Linker Design Service

Alfa Cytology - ADC Development Platform

Linker design service delivers rationally engineered bifunctional linkers that balance serum stability with precisely timed dual-payload release for next-generation dual-target ADCs. Alfa Cytology leverages state-of-the-art conjugation chemistry, high-resolution analytics, and extensive structure-activity expertise to provide tailored linker solutions for complex ADC development projects.

Introduction to Linker Design

Linker design in antibody-drug conjugates and related platforms involves the rational, data-driven selection of chemical spacers that securely tether cytotoxic payloads to the carrier while simultaneously governing systemic pharmacokinetics and payload-release kinetics. An effective linker must therefore exhibit high serum stability, predictable and reproducible cleavage by defined intracellular or tumoral triggers, and minimal alteration of overall conjugate hydrodynamics or antigen-binding affinity.

Fig 1. Classification of linkers in ADCs. (SHEYI R, et al., 2022)

Key Factors Influencing Linker Design

Triggerable Cleavage Mechanism

A well-tuned linker stays inert in systemic circulation yet cleaves rapidly in defined intracellular niches—acidic endosomes, reductive cytosol, or enzyme-rich lysosomes—thereby synchronizing payload release with maximal cellular susceptibility.

Hydrophilicity and Solubility Balance

Incorporating moderate polarity through short hydrophilic spacers curbs self-aggregation, tempers nonspecific uptake, and supports high-concentration handling during formulation without compromising membrane permeability.

Spacer Length and Steric Architecture

An optimized spacer projects the payload clear of the antibody's binding interface, reducing steric clash while preserving internalization efficiency and granting hydrolases or reductases unobstructed access to the scissile bond.

Our Services

Alfa Cytology combines deep expertise in conjugation chemistry with rigorous quality oversight to craft bespoke linker architectures tailored to dual‑payload ADC requirements. Drawing on a multidisciplinary team, it meticulously optimizes stability, release kinetics, solubility, and manufacturability, ensuring every linker aligns precisely with the program's performance specifications.

Stability Screening

Linker prototypes are incubated in serum-mimicking and buffered environments across multiple time points to quantify hydrolytic and enzymatic resilience. Comparative stress profiles (pH, redox, and temperature challenges) establish half-life benchmarks and identify failure modes before the linker advances to conjugation studies.

Payload-Carrier Conjugation Testing

Candidate linkers are coupled to representative payloads and antibody or protein carriers under optimized stoichiometry to evaluate reaction efficiency and drug-to-antibody ratio consistency. Post-conjugation analyses confirm that the final construct retains antigen affinity, maintains colloidal stability, and shows no premature payload release under physiological conditions.

Workflow of Linker Development

Linker Design & In-Silico Screening
Define the desired release trigger (pH, reductive, enzymatic) and use cheminformatics to model cleavage kinetics, hydrophobicity, and conjugation compatibility with chosen payloads and antibody attachment sites.

Synthetic Prototyping & Conjugation Feasibility
Synthesize a panel of candidate linkers, evaluate their reactivity toward engineered attachment handles, and generate small-scale ADC conjugates to measure initial drug to-antibody ratio and coupling efficiency.

Stability Profiling & Release Kinetics Optimization
Expose prototype conjugates to thermal, oxidative, and trigger specific conditions, quantifying intactness and cleavage rates; iterative chemistry refinement balances systemic stability with timely intracellular release.

Leveraging a multidisciplinary team and predictive molecular modeling, Alfa Cytology devises bespoke linker architectures that balance biostability, tuned release kinetics, and seamless manufacturability for sophisticated ADC programs. Should you require additional details or wish to discuss collaborative possibilities, please do not hesitate to contact our team.

Reference

SHEYI R, DE LA TORRE B G, ALBERICIO F. Linkers: An Assurance for Controlled Delivery of Antibody-Drug Conjugate [J]. Pharmaceutics, 2022, 14(2).

For research use only, not for clinical use.

DuoADC™: Precision Engagement, Amplified Efficacy

Online Inquiry

Name *

Email *

Phone

Services Interested *

Project Description

Please note that we are not a pharmacy or clinic, so we are unable to see patients and do not offer diagnostic and treatment services for individuals.